Competing Through Complexity: Models To Manage Mature Products

By 2034, only 10% of 2024 biopharma revenues will come from drugs still under patent, down from a historical average of 23%. That compression is arriving alongside pricing reform, tightening regulatory requirements, and geopolitical pressure on supply chains, leaving little room for ad hoc portfolio decisions.

For executives managing mature product portfolios, the core question is no longer whether to outsource but how to do it in a way that fits your organization's actual operating model. This white paper introduces a four-step framework built around four company archetypes: Builders focused on pipeline advancement, Optimizers protecting margins through cost discipline, Orchestrators managing complexity across global markets, and Opportunists moving quickly through acquisitions and divestitures.

Each archetype maps to distinct outsourcing structures, from outcomes-based partnerships and modular regulatory relief to hub-and-spoke integrated models and build-operate-transfer arrangements. A structured self-assessment across six dimensions (strategic intent, bandwidth, portfolio complexity, financial posture, outsourcing maturity, and risk tolerance) helps you confirm your archetype and identify where current approaches may be creating friction.

Use this framework to pressure-test your mature product strategy against your operating realities before your next portfolio review.